Predicting the clinical efficacy of generic formulations of ceftriaxone

Journal of Chemotherapy

Volumn 17, Issue SUPPL. 2, 2005, Pages 33-40

  Schito, Gian Carlo ^a   Keenan, M H J ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b Micron Research Ltd   (United Kingdom)

Author keywords

Ceftriaxone; Generics; PK PD; Rocephin

Indexed keywords

'AXON'; BROADCEF; CEFAXONA; CEFAXONE; CEFIXIME; CEFTREX; CEFTRIAXONA GI; CEFTRIAXONA SODIUM; CEFTRIAXONE; CEFTRIAXONE CEF3; DESFIN; ELPICEF; GENERIC DRUG; KGE; LGP; MERCEFEX; NOVOCEF; OFRAMAX; TITAN; TRIJEC; UNOCEF; VENTRAXIN;

ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATION; DRUG EFFICACY; DRUG FORMULATION; HUMAN; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PLEURA FLUID; PREDICTION; RESPIRATORY TRACT INFECTION; RISK BENEFIT ANALYSIS; STREPTOCOCCUS PNEUMONIA;

EID: 28044445395     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.supplement-2.33     Document Type: Article

References (37)

1. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 (Suppl 3): 38-44.
2. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47 (2): 129-140.
3. Leggett JE, Fantin B, Ebert S et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159 (2): 281-292.
4. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22 (1-2): 89-96.
5. Andes D, Anon J, Jacobs MR, Craig WA. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med 2004; 24 (2): 477-502.
6. Drusano GL, Goldstein FW. Relevance of the Alexander Project: pharmacodynamic considerations. J Antimicrob Chemother 1996; 38 (Suppl A): 141-154.
7. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15 (3): 255-259.
8. Brogden RN, Ward A. Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration. Drugs 1988; 35 (6): 604-645.
9. Stratton CW, Anthony LB, Johnston PE. A review of ceftriaxone: a long-acting cephalosporin. Am J Med Sci 1988; 296 (3): 221-222.
10. Barson WJ, Miller MA, Brady MT, Powell DA. Prospective comparative trial of ceftriaxone vs conventional therapy for treatment of bacterial meningitis in children. Pediatr Infect Dis 1985; 4 (4): 362-368.
11. Lin TY, Chrane DF, Nelson JD, McCracken GH Jr. Seven days of ceftriaxone therapy is as effective as ten days treatment for bacterial meningitis. JAMA 1985; 253 (24): 3559-3563.
12. Girgis NI, Kilpatrick ME, Farid Z, Mikhail IA, Bishay E. Ceftriaxone versus chloramphenicol in treatment of enteric fever. Drugs Exp Clin Res 1990; 16 (12): 607-609.
13. Lasserre R, Sangalang RP, Santiago L. Three-day treatment of typhoid fever with two different doses of ceftriaxone compared to 14-day therapy with chloramphenicol: a randomized trial. J Antimicrob Chemother 1991; 28 (5): 765-772.
14. Woodfield JC, Van Rij AM, Pettigrew RA, van der Linden AJ, Solomon C, Bolt D. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg 2003; 185 (1): 45-49.
15. Yuk JH, Nightingale CH, Quintiliani R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinet 1989; 17 (4): 223-235.
16. Patel IH, Chen S, Parsonnet M et al. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother 1981; 20 (5): 634-641.
17. Fraschini F, Braga PC, Scarpazza G et al. Human pharmacokinetics and distribution in various tissues of ceftriaxone. Chemotherapy 1986; 32 (3): 192-199.
18. Scaglione F, Raichi M, Fraschini F. Serum protein binding and extravascular diffusion of methoxyimino cephalosporins. Time courses of free and total concentrations of cefotaxime and ceftriaxone in serum and pleural exudate. J Antimicrob Chemother 1990; 26 (Suppl A): 1-10.
19. Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988; 32 (3): 289-297.
20. nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, Sept 27-30, 2002: p. 7.
21. NCCLS. Performance standards for antimicrobial susceptibility testing: Twelfth informational supplement (M100-S12). NCCLS (2002), Wayne, PA, USA.
22. Jacobs MR, Felmingham D, Applebaum PC, Grüneberg RN and the Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52 (2): 229-246.
23. Lambert PA, Conway BR. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin®. J Chemother 2003; 15 (4): 357-368.
24. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004; 3: 14 (http://www.annclinmicrob.com/content/3/1/14).
25. Klugman KP. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J Suppl 2002; 36: 3s-8s.
26. Giachetto G, Pirez MC, Nanni L et al. Ampicillin and penicillin concentration in serum and pleural fluid of hospitalized children with community-acquired pneumonia. Pediatr Infect Dis J 2004; 23 (7): 625-629.
27. Drusano GL, Goldstein FW. Relevance of the Alexander Project: Pharmacodynamic considerations. J Antimicrob Chemother 1996; 38 (Suppl A): 141-154.
28. Owens RC Jr, Tessier P, Nightingale CH, Ambrose PG, Quintiliani R, Nicolau DP. Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens. Int J Antimicrob Agents 2001; 17 (6): 483-489.
29. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p. 40.
30. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p. 28.
31. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p. 41.
32. th Interscience Conference on antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p. 180.
33. th Interscience Conference on antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p. 41.
34. Song JH, Jung SI, Ko KS et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004; 48 (6): 2101-2107.
35. Jones ME, Karlowsky JA, Blosser-Middleton RB et al. Longitudinal assessment of antipneumococcal susceptibility in the United States. Antimicrob Agents Chemother 2002; 46 (8): 2651-2655.
36. Thomas JK, Forrest A, Bhavnani SM et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42 (3): 521-527.
37. Odenholt I, Gustafsson I, Löwdin E, Cars O. Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model. Antimicrob Agents Chemother 2003; 47 (2): 518-523.